This information is for health professionals and service providers.
Motor neurone disease (MND) is a fatal, progressive, degenerative, neurological condition. It is a group of diseases in which the nerve cells controlling the muscles that enable us to move, speak, breathe, and swallow degenerate and die.
MND is also known as Amyotrophic Lateral Sclerosis (ALS) in other parts of the world.
The causes of the majority of cases of MND remain unknown. However, about 15% of cases are inherited (familial), and the genetic fault in about 60% of these cases is now known in Australian families. Current research also shows that many sporadic cases have a genetic component.
Average survival time after diagnosis is 2.5 years, but a minority, around 5 to 10%, will survive for more than 10 years. MND affects each person differently in terms of initial symptoms, rate and pattern of progression, and survival time.
MND occurs in all countries worldwide. The impact of ALS/MND on the community is usually measured by the incidence and prevalence of the disease. Incidence is the number of new cases added in a defined period, usually a year. Prevalence is the number of cases existing at any point in time.
Worldwide, the incidence of ALS/MND is 2 per 100,000 of the total population, while the prevalence is around 6 per 100,000 of the total population. Research has found that the incidence is higher in people aged over 50 years.
Although classified as a rare disease based on its prevalence, approximately 140,000 new cases are diagnosed worldwide each year. The lifetime risk of developing ALS/MND has been calculated to be 1/300.
In Australia, on average, each day two people die from MND and two people are diagnosed with MND.
Mortality rates due to MND are relatively high in all age groups. The mortality rate is estimated to be 3.14 per 100,000 across the entire population, which was equivalent to 752 deaths due to MND in 2015. Approximately 55% of deaths occur in males. Deaths associated with MND are typically due to respiratory failure as a result of weakened respiratory muscles.
The global incidence of ALS varies between 1 and 2.6 cases per 100,000 people per year, with the average age of onset ranging from 54 to 67 years old. The prevalence of ALS increases with age, reaching 1/5000 among people aged 70–79 years old. Consequently, as the population ages, the world’s total number of cases is expected to exceed 375,000 by 2040.
Because of the lack of a reliable diagnostic test, the absence of validated biomarkers, and phenotypes easily confounded with other MNDs, including primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA), diagnosis is delayed by approximately 11–12 months.
Currently, diagnosis is based on a set of clinical criteria (El Escorial and revisions, and Awaji-Shima criteria) that can be used to stratify patients according to the area of initial onset and the progression of symptoms (Connolly et al 2020).
The incidence of ALS is about 2 per 100,000 person-years, and the prevalence is about 5 per 100,000 persons. Because of the low prevalence, the average primary care physician will see 1 person in their lifetime, a typical UK neurologist will diagnose about 2 people a year, while a tertiary referral centre will see more than 100 people.
Despite the low incidence, however, ALS is not particularly infrequent. The lifetime risk is about 1 in 300 by the age of 85, with the risk increasing steadily, at least until about the eighth decade of life. This is very similar to the risk for multiple sclerosis in the UK (Martin et al 2017).
Contrary to earlier assumptions, the incidence of ALS has been shown to differ based on ancestral origin; studies in populations of European origin have shown a crude incidence of >3 cases per 100,000 individuals, but incidence rates are lower in East Asia (around 0.8 per 100,00) and South Asia (0.7 per 100,000).
In some regions (such as Guam and the Kii peninsula of Japan), the reported incidence was very high, but dropped substantially over the past 30 years for reasons that remain unclear.
In areas where different ancestral populations live in close proximity (as in North America), the incidence rates of ALS in indigenous populations are particularly low (0.63 cases per 100,000 individuals), whereas reported incidences in regions of relatively homogeneous populations (such as Ireland, Scotland and the Faroe Islands) are high (2.6 cases per 100,000 individuals) (Hardiman et al 2017).
MND onset is insidious. Initial symptoms may be mild and can include stumbling from leg muscle weakness, difficulty holding objects from hand muscle weakness, slurred speech and swallowing difficulties from tongue and throat muscle weakness, or shortness of breath from respiratory muscle involvement.
Some people may present with frontotemporal cognitive changes. Emotional responses may be more easily triggered, and the person with MND may be aware of laughing and crying more readily than previously.
Cramps and muscle twitching are also common symptoms.
The average age of onset is most commonly middle age and older.
Typically, people present with symptoms in one muscle group, for example, weakness and wasting of one hand or a unilateral foot drop. MND can be categorised based on sites of involvement at presentation and the balance between lower motor neurone and upper motor neurone features.
The demarcation between the different MND clinical groups is frequently blurred. As the disease progresses, considerable overlap may occur, resulting in more generalised muscle wasting and weakness.
Sensory symptoms or signs are rare and should lead to review of the diagnosis.
The motor nuclei controlling eye movements and the voluntary pelvic sphincter muscles usually remain intact.
The majority of ALS cases (~70%) have spinal onset, usually presenting with focal limb weakness such as foot drop or a weak hand. The disease then tends to spread contiguously, starting in distinct focal regions of the body and propagating from the primarily affected area to adjacent secondary sites.
In 25% of ALS cases, symptoms develop initially in the bulbar-innervated muscles. Bulbar-onset ALS is more common in women, especially after 70 years (M:F ratio 1:1.6). Dysarthria almost always predates dysphagia, and cognitive impairment is often present. Approximately 3% to 5% of patients present with respiratory or cognitive onset. Thoracic spinal-onset ALS can present as truncal weakness or respiratory impairment and is associated with poor prognosis, with a mean survival time of just 1.4 years.
Cognitive-onset ALS patients usually present symptoms characteristic of frontotemporal dementia (FTD), such as changes in behaviour, personality and cognition, which are all suggestive of frontal impairments.
In summary, the initial site of symptom onset varies among ALS patients from classic limb-onset to rare cognitive-onset phenotypes, and a poor prognosis is often associated with bulbar and respiratory onset (Connolly et al. 2020).
(ALS) is a progressive, paralytic disorder characterised by degeneration of motor neurons in the brain and spinal cord. It begins insidiously with focal weakness but spreads relentlessly to involve most muscles, including the diaphragm. Typically, death due to respiratory paralysis occurs in 3 to 5 years.
Motor neurons are grouped into upper populations in the motor cortex and lower populations in the brain stem and spinal cord; lower motor neurons innervate muscle. When corticospinal (upper) motor neurons fail, muscle stiffness and spasticity result.
When lower motor neurons become affected, they initially show excessive electrical irritability, leading to spontaneous muscle twitching (fasciculations); as they degenerate, they lose synaptic connectivity with their target muscles, which then atrophy.
ALS is the most frequent neurodegenerative disorder of midlife, with an onset in the middle-to-late 50s. An onset in the late teenage or early adult years is usually indicative of familial ALS. The time from the first symptom of ALS to diagnosis is approximately 12 months, a problematic delay if successful therapy requires early intervention.
Because an abundance of ALS genes have now been identified, it will probably be informative to re-analyse this epidemiologic profile of ALS with stratification according to genetically defined subtypes (Brown and Al-Chalabi 2017).
MND can be classified into four main types based on the pattern of motor neuron involvement and where symptoms begin.
Amyotrophic lateral sclerosis (ALS)
both upper and lower motor neurons are affected
limb muscle weakness and wasting
ALS is the most common type, characterised by muscle weakness and stiffness, overactive reflexes and, in some cases, rapidly changing emotions. Initially, the limbs stop working properly. Later, the muscles of speech, swallowing, and breathing are usually also affected. ALS is the term commonly applied to MND in many parts of the world.
Progressive bulbar palsy (PBP)
both upper and lower motor neurons are affected
speech and swallowing muscle weakness and wasting
When ALS begins in the muscles of speech and swallowing, it is designated progressive bulbar palsy. Progressive bulbar palsy (PBP), also called progressive bulbar atrophy, involves the brain stem, the bulb-shaped region containing lower motor neurons needed for swallowing, speaking, and chewing.
Symptoms include pharyngeal muscle weakness (affecting swallowing), weak jaw and facial muscles, progressive loss of speech, and tongue muscle atrophy. Limb weakness with both lower- and upper-motor-neuron signs is almost always evident but less prominent.
Pseudobulbar palsy shares many of the symptoms of progressive bulbar palsy (PBP) and is characterised by degeneration of upper motor neurons that transmit signals to the lower motor neurons in the brain stem. Affected individuals progressively lose the ability to speak, chew, and swallow.
Progressive weakness in facial muscles leads to an expressionless face. Individuals may develop a gravelly voice and an increased gag reflex. People with PBP or pseudobulbar palsy may have outbursts of emotional lability eg; laughing or crying uncontrollably.
Progressive muscular atrophy (PMA)
lower motor neurons are affected
slower rates of progression and significantly longer survival compared to ALS and PBP
PMA is characterised initially by lower motor neurone signs, resulting in more generalised muscle wasting and weakness, absent reflexes, weight loss, and muscle twitching. PMA can be the hardest form of MND to diagnose accurately.
Weakness typically starts in the hands and then spreads to the lower body, where it can be severe. Other symptoms may include muscle wasting, clumsy hand movements, fasciculations, and muscle cramps. Trunk muscles and respiration may also be affected.
Recent studies indicate that many people diagnosed with PMA subsequently develop upper motor neuron signs. This can lead to reclassification as ALS. PMA may begin in the arms (flail arm type) or the legs (flail leg type).
Primary lateral sclerosis (PLS)
upper motor neurons are affected
very rare and diagnosis is often provisional
PLS affects the upper motor neurons of the arms, legs, and face. It occurs when specific nerve cells in the motor regions of the cerebral cortex gradually degenerate, making movements slow and effortful.
The disorder often affects the legs first, followed by the body, trunk, arms, and hands, and finally the bulbar muscles. Speech may become slowed and slurred.
When affected, the legs and arms become stiff, clumsy, slow, and weak, leading to an inability to walk or carry out tasks requiring fine hand coordination. Balance problems may lead to falls. Affected individuals commonly experience pseudobulbar affect and an overactive startle response.
MND/FTD
A small proportion (5–15%) of people with MND will receive a diagnosis of ‘motor neurone disease with fronto-temporal dementia’ or MND/ FTD. Often, dementia symptoms precede motor symptoms, sometimes by several years.
Five major clinical phenotypes were determined and included ALS bulbar onset, ALS cervical onset and ALS lumbar onset, flail arm and leg, and primary lateral sclerosis (PLS). Of the 1834 registered patients, 1677 (90%) could be allocated a clinical phenotype. ALS bulbar onset had a significantly shorter survival than all other clinical phenotypes (p<0.004). There were delays in the median time to diagnosis of up to 12 months for the ALS phenotypes, 18 months for the flail limb phenotypes and 19 months for PLS (Talman et al 2016).
With profound clinical, prognostic, neuropathological, and now genetic heterogeneity, the concept of ALS as one disease appears increasingly untenable. This background calls for the development of a more sophisticated taxonomy, and an appreciation of ALS as the breakdown of a wider network rather than a discrete vulnerable population of specialised motor neurons (Turner et al 2013).
Amyotrophic lateral sclerosis (ALS) is characterised phenotypically by progressive weakness and neuropathologically by loss of motor neurons. Phenotypically, there is marked heterogeneity. Typical ALS has mixed upper motor neuron (UMN) and lower motor neuron (LMN) involvement. Primary lateral sclerosis has predominant UMN involvement. Progressive muscular atrophy has predominant LMN involvement. Bulbar and limb ALS have predominant regional involvement. Frontotemporal dementia has significant cognitive and behavioural involvement. These phenotypes can be so distinctive that they would seem to have differing biology. However, they cannot be distinguished, at least neuropathologically or genetically (Ravits et al 2013).
Kennedy’s Disease
Kennedy’s disease (KD), also known as X-linked spinobulbar muscular atrophy (SBMA), is an inherited disorder of the lower motor neurons. Due to similar symptoms, people with KD are sometimes misdiagnosed as having MND. Kennedy's disease is characterised by slowly progressive weakness and wasting of muscles with only lower motor neurone involvement and other features.
Kennedy's disease is an inherited disorder affecting adult males
Females who have a father with KD are inevitably KD gene carriers, and their sons (and daughters) have a 50% chance of inheriting the KD gene
Female gene carriers do not usually develop any KD symptoms
Males who have inherited the gene will develop KD symptoms as adults
Kennedy's disease cannot be passed from father to son
Clinically, the sporadic and familial forms of MND are indistinguishable.
familial MND accounts for about 10% of all MND cases
MND is sporadic in about 90% of cases, developing with no clearly identifiable causes
In recent years, the pace of gene mutation discovery has accelerated due to technological advances and a concerted international collaborative approach, with many mutations affecting small cohorts of people with MND now identified.
It is now possible to test for mutations in SOD1, TDP43, FUS, C9orf72, and other recently identified genes in a person diagnosed with familial MND.
Research is increasing our understanding of the mechanism by which these mutations cause MND and may lead to treatments which can prevent or delay the onset of MND in someone with an MND-related genetic mutation. Clinical trials of therapies targeting SOD1 and C9orf72 mutations are currently underway.
It is becoming apparent that many sporadic MND cases also have underlying genetic mutations. As we discover more MND-causing gene mutations in both familial and sporadic forms of MND, and in light of new personalised therapies in development, offering genetic testing to all people diagnosed with MND may become routine practice. This will require careful discussion with the person diagnosed and their family, along with professional genetic counselling and access to up-to-date, evidence-based information.
The number of clinically actionable results is likely to increase with the anticipated development of new genetic-therapy approaches for ALS. Previous genetic studies of ALS have been largely retrospective and were therefore unable to determine the utility of genetic screening in the clinic. In contrast, the present study strongly suggests that routine genetic testing should be offered in both patients with familial ALS and those with sporadic ALS, at least in our population (Shepheard et al 2021).
Five to 10% of ALS is genetically transmitted mainly by way of dominant gene mutations, and these numbers increase to as high as 15–20% when known genes are tested in patients who were thought to have sporadic disease. Approximately 60–70% of FALS pedigrees have genes that have now been identified, the main ones being SOD1, TARDBP, FUS, C9ORF72, OPTN, VCP, UBQLN, and PFN1 (reviewed in (65)). Clinical phenotype heterogeneity of FALS is as characteristic and as vast as SALS, and no clinical features easily distinguish one from another. Remarkably, this clinical phenotype heterogeneity is even seen in the same mutation in the same gene in the same kinship, implying phenotype is likely determined by factors other than the molecular cascade it triggers. However, some trends exist. Mutations in SOD1 and FUS tend to cause predominantly LMN syndromes. Mutations in TARDBP tend to begin in the upper extremity and to progress slower than average. Mutations in SOD1, TARDBP and FUS cause mostly motor syndromes and only rarely associated FTD. Mutations in FUS cause a juvenile as well as adult motor neuron disease syndrome. Mutations in C9ORF72 are as likely to cause FTD as ALS, often with psychosis. The ‘A4V mutation in SOD1 ALS is rapid while the ‘D90A’ mutation, unusual in that it is recessive, slow and indolent (Ravits et al 2013).
In most cases of MND, the cause is unknown.
Of the 5-10% of people who develop the familial form of MND, approximately 60–70% of genes involved have now been identified. As genetic factors are identified and metabolic pathways become clearer, the potential environmental factors to test may become more obvious.
Our understanding of the genetic basis of MND is increasing rapidly, but the relationship between genetic risk, environmental exposure and phenotype remains largely unknown, particularly in sporadic MND.
Several causes have been proposed to contribute to MND development. These include:
genetic factors
physical trauma/exercise
infection by viral agents
gut microbiomes
exposure to environmental toxins and chemicals
A number of different mechanisms that can affect the health of motor neurons are thought to contribute to MND:
protein aggregation
glutamate toxicity
mitochondrial dysfunction
dysfunctional signaling pathways
free radical damage
immune-mediated damage
loss of growth factors required to maintain motor neurone survival
These may act individually or in combination to cause or contribute to the development of MND. Recent research suggests a six-step process in which genes, environment, and aging contribute to;the development of MND.
Research focused on environmental causes, such as high-intensity exercise and blue-green algae, understandably often provokes intense media and community interest. Some studies may report an association, but it is important to note that association is very different from cause.
More research is needed to better understand the impact of the environment, particularly on people with a genetic predisposition to MND. The causes and disease mechanisms section of the MND Association of England, Wales and Northern Ireland MND Research Blog provides an overview of recent research on potential causes of MND.
In conclusion, the current evidence supports a complex causal relationship between physical exercise and ALS. However, it is clear that, for the majority of individuals, the health benefits of a physically active lifestyle markedly outweigh the risks. The key objective for future research is to understand which individuals are at risk of developing ALS if they exercise excessively and provide appropriate lifestyle counselling. Our work goes some way towards developing this aim and in particular, we propose that C9ORF72 penetrance may be influenced by high levels of physical activity (Julian et al 2021).
Over 150 years have passed since ALS was first reported by Charcot and still the aetiology of the disease remains elusive. Although research is progressing and genetic studies continue to identify novel gene associations, many questions remain surrounding the pathological mechanisms associated with already established mutations, their role in the ALS phenotype, and the as yet undiscovered mechanisms that underlie sporadic onset of disease (Connolly et al 2020).
This study established a linear relationship between log incidence and log age onset in an Australia ALS population, consistent with a multistep process. Identification of these steps will likely be of therapeutic benefit (Vucic et al 2019).
ALS is considered a complex genetic disorder with a Mendelian pattern of inheritance in a proportion of cases, but no discernible family history in the rest. Mathematical models developed using population-based registers have suggested that individuals with ALS are likely to carry a number of at risk variants that interact with environmental factors through a series of at least 6 notional steps leading to disease manifestation. One of these steps is thought to be the genetic risk (from birth), but the interplay of environmental factors that lead to the remaining steps have yet to be defined. In transgenic mice, the genetic background can alter the phenotypic presentation of ALS suggesting that human disease phenotypes could also have a genetic basis, and that genomic and epigenomic “fingerprinting” could permit the clustering of different phenotypic manifestations into discrete underlying causes that are amenable to therapeutic intervention (Hardiman et al 2017).
The apparently homogeneous phenotype of predominantly motor degeneration that is ALS can result from many different causes: genetic, epigenetic, environmental, and internal. Thus, many different pathways converge on the final outcome of upper and lower motor neuron death. Careful analysis of incidence data in European population registers shows that, on average, each pathway comprises six molecular steps. The model explains many otherwise enigmatic features of ALS, such as the increasing risk with age, genetic pleiotropy (the same gene variation can result in different diseases), age-dependent penetrance of disease genes, the difficulty in identifying a single environmental cause, the observation that ALS appears to start in one region and spread, and that it is specific to motor neurons but can affect other cell types. The next challenge is to understand the extent to which the pathways overlap and therefore might be amenable to a common treatment strategy. Although ALS remains a uniformly fatal diagnosis, accelerating advances in our understanding bring the hope that an effective treatment can be found for this devastating disease (Martin et al 2017).
Our findings support the hypothesis that a multistep process requiring just six distinct steps leads to the onset of amyotrophic lateral sclerosis. This provides hope that the identification of the steps could therefore lead to preventive or therapeutic avenues that have not yet been examined. The consistency of our findings across five western European populations and in both sexes suggests that the underlying mechanism is similar, and increases our confidence in the validity of the results. This hypothesis provides an explanation for several intriguing features of amyotrophic lateral sclerosis and means that environmental studies are essential even in people at high risk because of inherited genetic susceptibility (Al-Chalabi et al 2014).
Approved therapies
Currently, only two neuroprotective therapies are available, and both have only modest effects on the course of the disease.
Riluzole is an anti-glutamate medication that appears to block glutamate release from neurons. Riluzole is manufactured under the names Rilutek™ and APO-Riluzole. In Australia, riluzole is available to eligible people at a subsidised price on the Pharmaceutical Benefits Scheme (PBS) with an authority prescription.
Teglutik® (riluzole), a liquid formulation (for ease of swallowing or use via PEG tube) of riluzole, distributed by Seqirus (Australia) Pty Ltd, was listed on the PBS in April 2019 under the same prescribing conditions as Rilutek™ and APO-Riluzole.
Edaravone (Radicava) has been shown to provide a limited improvement in survival in a small subset of people with ALS/MND. It works by suppressing oxidative stress and is administered via intravenous infusions. Edaravone has been approved in several countries but not by the Therapeutic Goods Administration (TGA) in Australia.
The mainstay of treatment for people living with MND is coordinated multidisciplinary care and timely access to interventions to manage symptoms.
This review indicates that riluzole treatment may extend survival by 6–19 months, which is far greater than the 2- to 3-month survival benefit reported in original pivotal RCTs. Real-world evidence studies provide valuable information concerning characteristics among the broad patient population observed in clinical practice and physician treatment practices outside clinical trials. This information is necessary to guide treatment decisions and reimbursement and payment decisions. This analysis of population studies of patients with ALS was conducted to determine if the observed survival benefit of riluzole exceeds what was demonstrated in pivotal RCTs (Andrews et al 2020).
No therapy offers a substantial clinical benefit for patients with ALS. The drugs riluzole and edaravone, which have been approved by the Food and Drug Administration for the treatment of ALS, provide a limited improvement in survival. Riluzole acts by suppressing excessive motor neuron firing, and edaravone by suppressing oxidative stress. Numerous other compounds that have been investigated have not been shown to be effective. Currently, the mainstay of care for patients with ALS is timely intervention to manage symptoms, including use of nasogastric feeding, prevention of aspiration (control of salivary secretions and use of cough-assist devices), and provision of ventilatory support (usually with bilevel positive airway pressure). Some interventions raise serious ethical issues, such as whether to perform tracheostomy for full ventilation and, if so, when and how to withdraw respiratory support once it has been instituted.
Studies in cells, mice, and humans support the view that several types of reagents (e.g., antisense oligonucleotides and AAV-delivered microRNA) inactivate production of toxic gene products and thus may be therapeutic in ALS mediated by genes such as SOD184-87 and C9ORF72. Indeed, clinical trials investigating the use of antisense oligonucleotides to silence SOD1 have begun.
One can anticipate continued progress in understanding the biology of ALS. There is no doubt that high-throughput genetics, combined with improved clinical phenotyping, will further refine the genetic landscape of ALS. As thousands of full genome sequences become available, it will be feasible to explore the possibility that complex interactions among multiple gene variants explain not only familial ALS but also sporadic ALS. The exploration of environmental factors in sporadic ALS will expand, with a focus on the internal environment represented by the microbiome. The ultimate proof of our understanding of the biology of ALS will hinge on our ability to modify the clinical course of the disease (Brown and Al-Chalabi 2017).
Riluzole was the first FDA approved treatment for ALS, and, although the mechanism of action is poorly understood, is speculated to reduce glutamatergic neurotransmission, by blocking voltage-gated sodium channels on presynaptic neurons. In the original trial, Riluzole, increased 18-month survival of patients by 3 months compared with placebo, but had no significant effect on muscle strength. Riluzole is a relatively safe drug, although the most common adverse effects are an increase in liver enzymes and asthenia (that is, a lack of energy) and some cases of fatal hepatic failure and pancreatitis have been reported. In addition to the traditional tablet form of the drug, an oral suspension has been produced and marketed in some countries for patients who are unable to swallow solid forms of the drug, owing to severe dysphagia. Edaravone, which is thought to act as an anti-oxidant agent has a beneficial effect on progression in a highly selected cohort of patients with early onset and rapidly progressive disease, and accordingly, has been licensed by the US FDA but not by the European Medicines Agency. Whether Edaravone should be provided to all patients of ALS regardless of clinical presentation is a matter of debate (Hardiman and others, 2017).
Clinical trials
The Australian New Zealand Clinical Trials Registry lists clinical trials, including ALS/MND studies in Australia and New Zealand, as well as trials from across the globe that have been completed, are currently recruiting, or are pending. Over 80 ALS/MND clinical trials are currently being conducted worldwide. The Clinical Trial page on this website provides information on those being conducted in Australia. The ALS Signal: Clinical Research Dashboard developed by the organisation I Am ALS illustrates and lists clinical trials being undertaken globally.
Special Access Scheme
The Therapeutic Goods Administration (TGA) manages the Special Access Scheme (SAS). SAS refers to arrangements which provide for the import and/or supply of an unapproved therapeutic good for a single patient, on a case-by-case basis. Registered medical practitioners, preferably the treating doctor, make SAS applications to the TGA.
Off-label prescribing
Sometimes a medicine may be licensed for one condition but could be used to treat other conditions or illnesses. This is referred to as 'off-label' use of an 'unlicensed medicine'. Off-label prescribing is when a registered medicine is prescribed for a use not included in the approved product information.
Doctors may prescribe an unlicensed or off-label medication if they believe it is likely to be effective for their patient and the benefits outweigh the potential side effects or risks.
ALS Untangled provides reviews of alternative and off-label MND drugs by clinicians and scientists.
Shoesmith et al 2021, Canadian best practice recommendations for the management of amyotrophic lateral sclerosis: refer - disease-modifying therapies and medication alignment recommendations - table 1
Andersen et al 2012, EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis, Neuroprotective treatment/disease-modifying treatment recommendations:
Patients with ALS should be offered treatment with riluzole 50 mg twice daily (level A).
Initiate treatment as early as possible after diagnosis (GCPP). Discuss realistic expectations for treatment effects and potential side effects with the patient and caregivers (GCPP).
Patients with progressive muscular atrophy, primary lateral sclerosis, or hereditary spastic paraplegia should, as a rule, not be treated with riluzole (GCPP).
Irrespective of familial disposition, all patients with a symptomatic progressive MND and carrying a SOD1 gene mutation should be offered treatment with riluzole (GCPP).
Currently, there is insufficient evidence to recommend treatment with vitamins, testosterone, antioxidants such as co-enzyme Q-10 and ginkgo biloba, intravenous immunoglobulin therapy, cyclosporin, interferons, Copaxone, KDI tripeptide, neurotrophic factors (including BDNF, IGF-1 and mecasermin rinfabate), ceftriaxone, creatine, gabapentin, minocycline, stem cells or lithium (GCPP).
National Institute for Health and Clinical Excellence (2001) NICE Guideline: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease
International Alliance of ALS/MND Associations, webinar series 2021:
Biomarkers - discussion chaired by Dr David Taylor, ALS Canada
Optimizing Clinical Trial Design - discussion chaired by Dr Gethin Thomas, MND Australia
Introduction to ALS/MND Genetics - Dr Kelly Williams and Professor Ammar Al Chalabi
Genetics Counselling and Testing - Dr. Adriano Chiò, Dr Alisdair McNeill, Jennifer Roggenbuck
Stem Cells Australia, information on stem cells and motor neurone disease